People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Other Health Care, Other, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| HistoSonics, Inc. | — | Other Health Care | Series D+ | $308.2M | $1.0B | 2020 |
| Endotronix Inc | — | Other Health Care | Series C | $116.1M | $1.6B | 2016 |
| SpectraWAVE, Inc. | — | Other | Series C | $66.7M | $375.6M | 2024 |
| Engage Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.6M | $238.0M | 2019 |
| Cyrano Therapeutics, Inc. | — | Pharma | Series A | $4.1M | $108.3M | 2020 |
Gerry Brunk at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gerry Brunk on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PAUL LAVIOLETTE | 2 | 12 |
| Kadir Kadhiresan | 2 | 4 |
| Brian Smith | 1 | 22 |
| Heath Lukatch | 1 | 10 |
| Marc Goldberg | 1 | 9 |
| Steven Hochberg | 1 | 9 |
| Fouad Azzam | 1 | 8 |
| David Neustaedter | 1 | 7 |
| ROBERT ZIESERL | 1 | 5 |
| Jon Freeman | 1 | 5 |
| JAMES ADOX | 1 | 5 |
| Stephen Collins | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Linda Tufts | 1 | 5 |
| V. Kadir Kadhiresan | 1 | 5 |
| Michael Blue | 1 | 4 |
| John Flavin | 1 | 4 |
| Takahide Koda | 1 | 3 |
| CHRIS DIMITROPOULOS | 1 | 3 |
| Mark Theeuwes | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.